Drug Approvals, License Applications, Partnerships, and Positive Results Underline Growth for Biotech Companies - Research

   Drug Approvals, License Applications, Partnerships, and Positive Results
     Underline Growth for Biotech Companies - Research Report on Vertex,
         Theravance, Array BioPharma, Immunomedics, and Cytokinetics

PR Newswire

NEW YORK, July 17, 2013

NEW YORK, July 17, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Vertex
Pharmaceuticals Incorporated (NASDAQ: VRTX), Theravance Inc. (NASDAQ: THRX),
Array BioPharma, Inc. (NASDAQ: ARRY), Immunomedics Inc. (NASDAQ: IMMU), and
Cytokinetics, Incorporated (NASDAQ: CYTK). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Vertex Pharmaceuticals Incorporated Research Report

On July 9, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced that
it has received an approval for KALYDECO (ivacaftor) from the Therapeutic
Goods Administration (TGA) of Australia. According to Vertex KALYDECO
(ivacaftor) is used for the treatment of cystic fibrosis (CF) in patients of
ages 6 and older, who have at least one copy of the G551D mutation in the
cystic fibrosis transmembrane conductance regulator (CFTR) gene. Simon Bedson,
Senior Vice President of International Commercial Operations for Vertex,
commented, "The approval of KALYDECO in Australia is an important milestone
for the cystic fibrosis community." Bedson added, "The rapid review and
approval by the TGA is a major step in making KALYDECO available for eligible
Australians." The Full Research Report on Vertex Pharmaceuticals Incorporated
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/ec92_VRTX]

--

Theravance Inc. Research Report

On July 12, 2013, Theravance Inc. (Theravance) and GlaxoSmithKline (GSK)
jointly announced that the license application for the use of fluticasone
furoate (FF) and vilanterol (VI) (proposed brand name RELVAR ELLIPTA) in
patients with chronic obstructive pulmonary disease (COPD) has been withdrawn
from the current Japanese New Drug Application (JNDA). The Companies reported
that the review of FF/VI for use in patients with asthma is continuing to
progress through the normal Japanese regulatory process as part of this JNDA.
Theravance and GSK also stated that they are currently determining next steps
and possible clinical studies of FF/VI for the treatment of Japanese patients
with COPD to support the resubmission. The Full Research Report on Theravance
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/f77e_THRX ]

--

Array BioPharma, Inc. Research Report

On July 10, 2013, Array BioPharma, Inc. (Array) and Loxo Oncology, Inc., a
biopharmaceutical company recently established and funded by Aisling Capital,
jointly announced that they have reached a multi-year license and
collaboration agreement for an Array-invented preclinical development
candidate and related intellectual property. Ron Squarer, CEO of Array,
stated, "We are delighted to enter into this collaboration with the goal of
rapidly bringing this exciting technology to cancer patients." Squarer
continued, "Array has partnered with a number of venture-backed companies
which continue to produce encouraging results; the venture-financed model of
drug discovery and development can cost-effectively identify novel candidates
and rapidly test the clinical hypothesis." The Full Research Report on Array
BioPharma, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.WSReports.com/r/full_research_report/e24e_ARRY ]

--

Immunomedics Inc. Research Report

On July 3, 2013, Immunomedics Inc. (Immunomedics) announced encouraging
results from the Phase Ib study with clivatuzumab labeled with the
radioisotope, yttrium-90 (^90Y), in patients with metastatic pancreatic cancer
who had received at least 2 prior treatments. Cynthia L. Sullivan, President
and CEO of Immunomedics, said, "We are very encouraged with these results, and
we believe this study demonstrated the feasibility of conducting clinical
trials in pancreatic cancer patients relapsed to 2 or more prior treatments.
We have made the strategic decision to move forward with a Phase III clinical
trial, positioning clivatuzumab in this setting as a therapy for patients with
advanced pancreatic cancer

who have few to no treatment options." Sullivan added, "We have designed and
vetted our protocol with key opinion leaders and FDA, selected our clinical
research organization, and plan to enroll the first patient into the Phase III
clinical trial by the end of this calendar year, or the beginning of 2014.
Most of our clinical trial sites will be in the US, with some additional sites
in the EU." Sullivan concluded, "For future clinical trials, KPS and number of
prior treatments will be considered as important survival prognosticators."
The Full Research Report on Immunomedics Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.WSReports.com/r/full_research_report/cc0f_IMMU ]

--

Cytokinetics, Incorporated Research Report

On July 8, 2013, Cytokinetics, Incorporated (Cytokinetics) announced an update
on the conduct of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and
Functional Improvement with Tirasemtiv in ALS). Cytokinetics reported that
over 450 patients have been enrolled in the study, which is designed to enroll
up to 500 patients with ALS. The Company's primary analysis of BENEFIT-ALS
will compare the mean change from baseline in the ALS Functional Rating Scale
in its revised form, or ALSFRS-R (a clinically validated instrument designed
to measure disease progression and changes in functional status), in patients
receiving tirasemtiv versus those receiving placebo. According to
Cytokinetics, the Company has already taken measures regarding the programming
error in the electronic data capture system controlling study drug assignment,
which caused 58 patients initially randomized to and treated with tirasemtiv
to receive placebo instead at a certain study visit and for the remainder of
the study. The Full Research Report on Cytokinetics, Incorporated - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.WSReports.com/r/full_research_report/5a39_CYTK ]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)